Desloratadine in Patients With Ulcerative Colitis

Sponsor
Tanta University
Study ID
NCT07333716
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Desloratadine — DRUG
    mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.
  • mesalamine — DRUG
    mesalamine 1000 mg three times daily for 3 months

Study Details

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.

Key Dates

First listed
Jan 12, 2026
Start date
Jan 26, 2026
Status verified
Jan 2026
Primary completion
Feb 28, 2027
Completion
Mar 31, 2027

Study Design

Enrollment
44 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Placebo Comparator: Group I (Control group)
    which will receive mesalamine (standard treatment ) 1000 mg three times daily for 3 months and serve as the control group
  • Active Comparator: Group II (Desloratadine group)
    which will receive mesalamine (standard treatment )1000 mg three times daily plus desloratadine 5 mg once daily for 3 months

Primary Outcome Measure

Change in disease activity and severity [ Time Frame: over a 3 month follow -up period ]

Central Contacts

Find similar trials

Nationwide
Ulcerative colitis trialsGastroenterology trialsInflammatory bowel disease trialsAutoimmune disease trials

Related Studies